Genmab A/S (NASDAQ:GMAB) Price Target Raised to $57.00

Genmab A/S (NASDAQ:GMAB) had its price target boosted by investment analysts at Morgan Stanley from $42.00 to $57.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley‘s target price suggests a potential downside of 0.61% from the company’s previous close.

Several other research firms have also weighed in on GMAB. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. New Street Research set a $43.00 price target on Genmab A/S in a report on Wednesday, July 22nd. JPMorgan Chase & Co. raised Genmab A/S from a “neutral” rating to an “overweight” rating in a research report on Monday. HC Wainwright boosted their price objective on Genmab A/S from $50.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Guggenheim upped their target price on Genmab A/S from $58.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.61.

Genmab A/S Trading Up 1.5%

GMAB traded up $0.86 during midday trading on Friday, hitting $57.35. The company’s stock had a trading volume of 4,410,995 shares, compared to its average volume of 2,457,160. Genmab A/S has a 52-week low of $23.62 and a 52-week high of $59.97. The firm has a 50-day moving average price of $36.64 and a two-hundred day moving average price of $30.47. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. The firm has a market cap of $35.79 billion, a P/E ratio of 45.18, a PEG ratio of 2.47 and a beta of 0.81.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.37 by $0.17. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.12 billion. On average, research analysts anticipate that Genmab A/S will post 1.22 earnings per share for the current year.

Institutional Trading of Genmab A/S

Institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Genmab A/S in the 3rd quarter worth about $177,000. Vise Technologies Inc. grew its position in shares of Genmab A/S by 41.6% during the 3rd quarter. Vise Technologies Inc. now owns 23,186 shares of the company’s stock valued at $827,000 after buying an additional 6,809 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Genmab A/S by 46.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,692 shares of the company’s stock valued at $629,000 after buying an additional 5,615 shares during the last quarter. Park Avenue Securities LLC raised its stake in Genmab A/S by 2.4% during the third quarter. Park Avenue Securities LLC now owns 11,258 shares of the company’s stock worth $402,000 after acquiring an additional 265 shares during the period. Finally, Signaturefd LLC raised its stake in Genmab A/S by 8.5% during the third quarter. Signaturefd LLC now owns 17,842 shares of the company’s stock worth $636,000 after acquiring an additional 1,400 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S News Summary

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Genmab’s cancer drug reportedly achieved the primary goals of a Phase III head-and-neck cancer study and reduced the risk of death by 50%, strengthening the potential for a meaningful new treatment option and supporting the stock’s recent move toward record highs. Genmab drug cuts death risk 50% in head and neck cancer trial
• Positive Sentiment: Guggenheim raised its Genmab price target from $58 to $80 and initiated or reiterated a “Buy” rating, implying substantial additional upside based on the trial success and broader pipeline prospects. Guggenheim Genmab recommendations
• Positive Sentiment: HC Wainwright lifted its price target from $50 to $70 while maintaining a “Buy” rating. Its updated quarterly forecasts are broadly stable to slightly higher, reinforcing expectations for earnings growth through 2027. HC Wainwright Genmab recommendations
• Positive Sentiment: Truist reaffirmed its “Buy” rating and raised its target from $45 to $67, adding to the positive sell-side momentum surrounding GMAB. Truist Genmab recommendations
• Neutral Sentiment: Some commentary suggests Genmab may still be undervalued after the trial wins, while another analysis recommends waiting before buying following the sharp rally. This highlights both continued upside potential and increased valuation and execution risk. Can Genmab Still Be Undervalued After Its Trial Wins?

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.